CMS Final Medicaid Drug Rebate Rule Details New Misclassification Penalties and Numerous Other Changes
FDA Law
SEPTEMBER 30, 2024
CMS did not finalize the price verification survey, which would have required manufacturers of 10 costly drugs selected annually to provide clinical information as well as information on production, distribution, research, and marketing costs, revenue and profit, and ex-U.S. Remarkably, manufacturers may not dispute a CMS notification.
59 
Let's personalize your content